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Understanding nucleus pulposus cell phenotype: A prerequisite 
for stem cell based therapies to treat intervertebral disc 
degeneration
Hyowon Choi1, Zariel I. Johnson1, and Makarand V. Risbud*
Department of Orthopaedic Surgery and Graduate Program in Cell and Developmental Biology, 
Thomas Jefferson University, Philadelphia, PA, U.S.A
Abstract
Intervertebral disc (IVD) degeneration and associated low back pain (LBP) remains a major 
burden to our society without a significant improvement in treatment strategies or patient’s quality 
of life. While the recent cell-transplantation studies for treatment of degenerative disc disease 
showed promising results, to better gauge the success and functional outcomes of these therapies, 
it is crucial to understand if transplanted cells give rise to healthy nucleus pulposus (NP) tissue. 
NP cell phenotype is unique and is defined by expression of a characteristic set of markers that 
reflect their specialized physiology and function. This review summarizes phenotypic markers that 
mirror unique physiology and function of NP cells and their progenitors and should be considered 
to measure outcomes of cell-based therapies to treat disc degeneration.
BACKGROUND
Degeneration of the intervertebral discs (IVDs) and associated back pain remain prevalent 
and costly conditions today, despite ongoing research and recent clinical advancements. It is 
estimated that two out of three adults will suffer from back pain at some time during their 
lifetime, and much of this pain is directly attributable to disc disease [1, 2]. In a recent 20-
year study, low back pain (LBP) was ranked the highest in number of years lived with 
disability; neck pain ranked fourth. In addition, LBP was fourth highest in disability-
adjusted life-year ranking – a measure of missed “healthy” years of life [3]. Costs from the 
disease continue to increase, with spine-related expenditures in the United States estimated 
at $85.9 billion for 2005. Unfortunately, from 1997 to 2005, a Medical Expenditure Panel 
Survey found no significant improvement in several parameters surveyed, including self-
assessed health status, functional disability, work limitations, and social functioning [4]. 
Moreover, one of the most common surgeries to relieve back pain stemming from 
degenerative discs – fusion – has been shown to negatively affect mechanics of surrounding 
discs [5]. It is clear from these statistics that there is a need for novel, effective strategies for 
the treatment of IVD degeneration.
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An early characteristic of disc degeneration is the loss of cell number in the inner, gelatinous 
nucleus pulpous (NP) of the disc [6, 7]. The NP of the healthy adult disc is cell-sparse and 
proteoglycan-rich, affording the tissue its high water content and, thus, mechanical function 
of distributing loads applied to the spine [8]. Resident NP cells are responsible for 
maintenance of this critical extracellular matrix through production of proteoglycans, mainly 
aggrecan, and collagens [9, 10]. Since the activity of NP cells underlies function of the disc, 
and their capacity to support the tissue declines with degeneration, one logical approach to 
alleviating the effects of disc degeneration is to regenerate or replace these resident cells.
Several studies have investigated cell-based therapy for treating disc degeneration. Use of 
endogenous disc progenitor cells or transplantation of mature disc cells or mesenchymal 
stem cells (MSCs) has been extensively explored. Direct transplantation of NP cells or 
chondrocytes, from both autologous and allogenic sources, has been proven to decrease 
degenerative phenotype in animal models [11-14]. Identification of an endogenous 
progenitor population within the disc has further expanded the possibility of cell-based 
therapy [15]. Finally, MSCs derived from bone marrow or other tissues have been 
extensively studied as a potential source of regeneration for the NP, and have shown 
promising results [16]. While these studies provide hope that stem cell therapy can be used 
to maintain disc health, several obstacles still remain. One critical component of a 
regenerative therapy is that the new tissue is able to replace or support function of diseased 
tissue. To recapitulate the healthy NP cell phenotype, it must first be clearly defined [17]. 
Thus, this review focuses on the key phenotypic characteristics of NP cells that must be 
mirrored in a successful cell replacement therapy, and provides a broad overview of stem/
progenitor cell based therapy for disc degeneration.
IDENTIFICATION OF DISC PROGENITOR CELLS
Although the turnover of disc cells is generally thought to be slow, minor regenerative 
processes have been observed in the IVD, especially in the outer regions of annulus fibrosus 
(AF) [18, 19] and possibly in the inner AF and the NP [20]. The idea of promoting disc cell 
self-renewal is supported by several studies showing evidence of stem cells or progenitor 
cells within the disc. From degenerative human disc tissue, Risbud et al. [21] identified cells 
that express CD105, CD166, CD63, CD49a, CD90, CD73, p75 low affinity nerve growth 
factor receptor, and CD133/1, all of which are characteristically expressed on BM-MSCs. 
These cells also showed osteogenic, adipogenic, and chondrogenic differentiation capacity 
when cultured in appropriate media [21]. Similarly, Brisby et al. [22] reported expression of 
OCT3/4, CD105, CD90, STRO-1, and NOTCH1 genes and proteins in degenerative human 
disc tissues. According to a study by Blanco et al., when compared with the BM-MSCs, NP-
derived MSCs had comparable morphology, immunophenotype, and differentiation 
capacity, with the exception that NP-derived MSCs could not differentiate into adipocytes 
[23]. Furthermore, Feng et al. [24] isolated AF cells from non-degenerative human discs and 
found that these cells express MSC markers including CD29, CD49e, CD51, CD73, CD90, 
CD105, CD166, CD184, and STRO-1, and the neuronal stem cell markers nestin and 
neuron-specific enolase. The authors also demonstrated that these AF cells had the ability to 
differentiate into adipocytes, osteoblasts, chondrocytes, neurons, and endothelial cells [24]. 
In accordance with these studies, Henriksson et al. [25] found in rabbit discs that both NP 
Choi et al. Page 2
Curr Stem Cell Res Ther. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
and AF contained 5-bromo-2’-deoxyuridine (BrdU) positive cells, indicating slow but 
ongoing cell proliferation. In the region of the AF border to ligament zone and the 
perichondrium region, a high number of BrdU positive cells were found at early time points, 
which substantially decreased at later time points, similar to the pattern of a stem cell niche. 
In a more recent study, Henriksson et al. [26] confirmed the presence of BrdU positive cells 
in the previously reported stem cell niche near the epiphyseal plate. Interestingly, BrdU 
positive cells found in this region in the 3-month-old rabbit were significantly reduced at 9-
months. Rather, in the older rabbits BrdU positive cells were found in a new niche in the 
mature AF [26].
Studies by Sakai et al. [27] and Yasen et al. [28] further confirmed the existence of a pool of 
endogenous progenitors within the disc. These two studies also emphasize the change in the 
progenitor pool with age and degeneration. Age-dependent reduction in the Tie2+ NP 
progenitor cell population in human and mouse [27] as well as reduction of progenitor cell 
marker expression in rabbit IVD [28] suggest there may be some difficulties in utilizing 
endogenous progenitors for disc repair simply due to reduced availability of the progenitor 
cells in aged discs (Figure 1). Still, results from these studies confirm the presence of 
endogenous progenitor/stem cells in a niche, and suggest that these cells can be used to 
replace old and damaged cells to replenish the disc structure.
PROGENITOR CELL MARKERS AND NOTCH SIGNALING IN IVD
Studies that have identified progenitor cells within the IVD have often used classical MSC 
markers recommended by the Mesenchymal and Tissue Stem Cell Committee of the 
International Society for Cell Therapy: CD90+, CD73+, CD105+, CD45-, CD34-, CD14-, 
CD11b-, CD79α-/CD19-, and HLA-DR- [29]. Additional markers expressed by the disc 
progenitor cells or used to determine localization of these cells in the disc include CD24, 
CD29, CD44, CD49a/e/f, CD51, CD56, CD63, CD73, CD133/1, CD166, CD184, OCT3/4, 
Notch receptors and ligands, C-KIT, KI67, STRO-1, Tie2, and GD2 [21-24, 27, 28]. Two 
additional criteria proposed by the International Society for Cellular Therapy for defining 
human MSC are 1) adherent property to plastic in standard culture condition, and 2) ability 
to differentiate into osteoblasts, adipocytes, and chondroblasts in vitro [29]. The latter of the 
two are especially critical in determining the pluripotency of the MSCs, and therefore 
important in identifying progenitor disc cells.
The Notch signaling pathway is essential for progenitor cell activity, proliferation, and fate 
determination in various tissues, and thus, its related molecules are utilized as stem/
progenitor cell markers. In IVD, Notch1 expression pattern resembled that of BrdU positive 
areas [25], and also correlated with the disc progenitor cell niche [30]. Noteworthy, the 
Notch signaling pathway is induced by hypoxia in disc cells [31]. Hiyama et al. [31] 
confirmed expression of Notch receptors and ligands in rat NP and AF tissues, and 
demonstrated that hypoxia increased expression of Notch1, Notch4, and Jagged2 mRNA in 
both tissues, and Jagged1 expression in AF. Inhibition of Notch signaling significantly 
reduced NP cell proliferation independent of oxemic tension. Interestingly, Hes1, a Notch 
target and also an important regulator of stem cell maintenance, was also induced by 
hypoxia in AF cells. Although not yet evaluated in NP cells, an earlier study by Gustafsson 
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et al. [32] shed a light on how Notch signaling may control progenitor cell differentiation in 
a hypoxia-dependent manner. In their study, the authors showed that hypoxia dependent 
inhibition of myogenic and neural precursor differentiation required activation of the Notch 
signaling pathway. Importantly, hypoxic activation of Notch signaling involved interaction 
between HIF-1α and notch intracellular domain (NICD), leading to subsequent inhibition of 
myogenic and neural differentiation.
Furthermore, Hiyama et al. [31] observed a trend of increased expression of Jagged1 and 
Jagged2, and possibly Notch4 and Hes1 in NP tissues from degenerative human IVDs, 
despite their probable low progenitor cell content. This observation can be explained by a 
recent study demonstrating that inflammatory cytokines, IL-1β and TNF-α, induced Notch 
signaling in NP cells by up-regulating Notch receptors and ligands by activating NF-κB and 
MAPK signaling [33]. Importantly, in degenerative human discs, Notch1, Notch2, and Hey2 
were up-regulated, and the increase in Notch2 was highest in mid-grade degenerate discs 
corresponding to the highest level of inflammatory cytokines. Thus, Notch signaling may be 
induced in response to inflammatory cytokines in the degenerative disc and act as a 
compensatory mechanism to revive endogenous cell population through proliferation [31, 
33].
These studies indicate that Notch signaling molecules can possibly be used as disc 
progenitor markers. Furthermore, Notch signaling may be essential in disc progenitor 
maintenance in hypoxic microenvironment, and targeting the involved molecules can be a 
therapeutic strategy for preventing IVD degeneration.
CELL-BASED THERAPY FOR DISC DEGENERATION
Cell-based therapy for disc degeneration involves promoting endogenous progenitor cells or 
transplanted MSCs to differentiate into mature disc cells for functional regeneration of the 
native tissue [16]. As described in studies demonstrating pluripotency of disc progenitor 
cells [23, 24, 34], disc progenitor cells can be a valuable source for tissue specific stem cell, 
or they can be stimulated endogenously to take the role of resident NP cells.
Transplantation of MSCs has been widely investigated and the results of several studies 
have shown benefits of this strategy [35-42]. Various studies have described induction of 
MSC differentiation into disc-like cells; growth factor treatment, specific culture conditions, 
co-culture with mature disc cells, and seeding onto a tissue scaffold have all been attempted 
[16]. Treatment of MSCs with TGFβ, IGF1, FGF2, or PDGF-BB can induce differentiation 
of these cells into NP-like cells [43, 44]. Co-culturing MSCs with mature NP cells for 7 days 
resulted in up-regulation of NP marker genes in MSCs [45]. Interestingly, this induction of 
MSC differentiation occurred only when there was a cell-cell contact between the two cell 
types. When NP cells from degenerative discs were co-cultured with MSCs, the MSCs 
differentiated into NP-like cells, while the degenerative NP cells increased their expression 
of matrix genes, TGFB1, and growth and differentiation factor 5 (GDF5) [46]. These studies 
suggest that introducing MSCs into the IVD will not only cause MSC differentiation into 
NP-like cells, but also will induce the endogenous degenerative cells to increase their own 
matrix production. Another method of inducing MSCs to NP-like cell differentiation by 
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using notochordal cell conditioned medium (NCCM). Culturing human MSCs in porcine 
NCCM resulted in greater accumulation of GAGs, increased collagen III, and decreased 
collagen II and Sox9 gene expression [47]. However, NCCM derived from notochordal cells 
in native tissue (NCT) as opposed to in alginate beads (NCA) induced higher GAG 
production and increased Sox9 and collagen II gene expression [48]. Interestingly, NCA-
derived medium had anti-fibrotic and minimally hypertrophic effect on MSCs evidenced by 
decreased collagen I and II and low collagen X gene expression [48]. On the other hand, 
when BMSCs or NP cells were co-cultured with notochordal cells in 3D hydrogel for 4 
weeks, no increase in matrix production was observed, possibly due to loss of notochordal 
cell phenotype during long-term culture [49]. Another recent study showed co-culturing 
porcine notochordal cells encapsulated in alginate beads with NP cells without direct cell-
cell contact in hypoxia resulted in higher aggrecan to collagen II gene expression ratio. The 
authors identified CCN2 in the medium of notochordal cell and NP cell co-culture as well as 
NCCM derived from 3D alginate bead-encapsulated notochordal cells [50]. While NCCM or 
notochordal cells can potentially direct MSCs differentiate into NP-like cells, further 
investigation is necessary to identify specific factors involved in this process.
One of the most distinct features of NP cells is their adaptation to their hypoxic 
microenvironment (discussed in detail below). It follows that hypoxia is essential in 
directing MSCs toward native disc cell phenotypes. Risbud et al. [51] encapsulated rat 
MSCs in 3-dimensional (3D) alginate hydrogels and cultured them in medium with TGFβ1 
under hypoxia, finding that this culture condition induced MSC differentiation towards an 
NP-like cell phenotype; the differentiated MSCs formed large aggregates and up-regulated 
GLUT-3, SOX9, MMP-2, collagen II, XI, and ACAN expression. Hypoxia also up-regulated 
the expression of CD44, CD166 and CD105. Stoyanov et al. [52] also reported that hypoxia 
with concurrent treatment of GDF5 induced human BM-MSCs to increase their ACAN and 
collagen II expression and GAG production, indicating the importance of hypoxia in MSC 
differentiation to disc cells. In a study of rabbit MSCs, when seeded into 3D nanofibrous 
poly(l-lactide) scaffold and treated with TGFβ1 under hypoxia, cells differentiated toward 
NP-like cells [53]. Importantly, the cells continuously expressed the functional NP-specific 
marker, HIF-1α.
Another important feature of NP cells for consideration in differentiation schemes is their 
origin. Resident cells of the NP are derived from the embryonic notochord, which is formed 
by convergence and extension of the chordamesoderm [54, 55]. An intriguing recent study 
suggests how notochord may have emerged through evolution [55]. The authors identified a 
group of mesodermal cells in the midline of Platynereis dumerilii, an invertebrate marine 
annelid, during development that expressed notochord-specific combination of genes. 
Expression of transcription factors (foxA, foxD, twist, soxD, soxE), signaling molecules 
(noggin, hedgehog), and guidance factors (netrin, slit), in combination with expression of 
brachyury was unique to the mesodermal midline cells in annelid, which strongly supported 
the similarity between these cells to the vertebrate chordamesoderm. Interestingly, the 
annelid midline mesodermal cells differentiated into a longitudinal muscle, the axochord, 
which secreted ECM abundant of collagen [55]. In NP, the fate of the notochord-derived 
cells and whether they are replaced by another cell type in the adult NP has been a debated 
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topic [15]. A recent report by Merceron et al., however, disproved the idea that NP cells 
trans-differentiate into chondrocyte-like cells. By lineage studies and TUNEL assay, the 
authors clearly showed that hypoxia inducible factor (HIF)-1α deletion in embryonic 
notochordal cells resulted in complete NP cell death before they were replaced by non-
notochordal cells [56]. Some groups have shown the cell population of the NP as 
heterogeneous, composed of both notochordal and chondrocyte-like cells [57, 58]. Several 
studies have pointed to a switch in the ratio of these notochordal to chondrocytic cells with 
aging or degeneration of the disc [57, 59, 60]. As such, it may be a better strategy to 
recapitulate features specific to the young, healthy NP cell. Indeed, a recent study by Liu et 
al. [61] showed that human induced pluripotent stem cells (hiPSCs) could be differentiated 
into notochordal cell (NC)-like cells by culturing them with pulverized porcine NP matrix, 
either with or without direct contact between the cells and the matrix. The differentiated 
cells increased expression of notochordal marker genes including brachyury, CK-8 (K8), 
and CK-18 (K18), and could be further differentiated to express ACAN and collagen II.
One NP marker critical in formation of the NP is Sonic hedgehog (SHH) that is secreted 
from the notochord during development. SHH and its receptor, patched (PTC) are expressed 
in the developing mouse notochord [62]; a fate mapping study later showed that it was 
specifically SHH-expressing cells of the notochord that will give rise to NP in mice [63]. 
Further work from Dahia lab has demonstrated that SHH plays an important role in 
signaling in the postnatal NP [64]. Interestingly, SHH signaling in the NP responds to 
canonical Wnt signaling, however activity of both signaling pathways is down-regulated in 
IVDs with ageing [65]. Re-activation of the Wnt signaling pathway in older IVDs increased 
expression levels of COL1A1, SOX9, and, chondroitin sulfate (CHSO4), ACAN, and 
brachyury. Another notochordal marker, brachyury [54], is required for differentiation and 
survival of the notochord [66], and its expression persists in mature NP cells of many 
species including humans [67-69]. However, in postnatal NP, the function of brachyury 
remains unknown, as do many of its transcriptional targets. Therefore, further work is 
necessary to elucidate their role in the adult disc.
Many in vivo studies using different degenerative IVD models have shown that 
transplantation of BM-MSCs into the disc can decelerate the degenerative process and 
promote regeneration [35-40]. Transplanted MSCs survive, proliferate, and acquire 
morphologic and functional phenotypes of disc cells. Studies by Sakai and colleagues 
demonstrated that transplanted MSCs expressed HIF-1/2α, HIF-1β, MMP-2, GLUT-1 and 
GLUT-3, as well as chondroitin sulfate, keratan sulfate, and collagens I, II, IV, all of which 
are similarly expressed by native NP cells [35-37]. In studies where human MSCs were 
transplanted into rat or porcine IVDs, results confirmed survival and differentiation of 
transplanted cells into disc-like cells [41,42]. Importantly, Yoshikawa et al. [70] reported 
successful transplantation of autologous BM-MSCs into IVDs of two human patients who 
were experiencing vacuum phenomenon with instability and were undergoing 
decompression surgery for spinal stenosis. During the surgery, autologous BM-MSCs 
seeded in a collagen sponge were transplanted into the degenerative IVD. Radiograph and 
CT showed improvement in the vacuum phenomenon at two years post-surgery. Discs that 
had undergone transplantation showed signs of regeneration as evaluated by high T2-
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weighted MRI signal intensity, indicative of high water content. More importantly, the 
patients’ symptoms were alleviated, strongly supporting the favorable results of MSC 
transplantation studies. In another clinical study, 26 patients with moderate to severe 
discogenic pain were injected with autologous bone marrow concentrate (BMC), which 
contained average 2,713 MSCs/mL [71]. At 12 months post-injection, the average Oswestry 
Disability Index (ODI) was reduced to 25.0 from over 30.0, and Visual Analogue Scale 
(VAS) to 33.2 mm from over 40.0 mm. Importantly, although all patients experienced pain 
alleviation, those who received BMC with greater than 2,000 MSCs/mL had significantly 
faster and greater decrease in ODI and VAS, indicating a correlation between MSC 
concentration and discogenic pain alleviation [71]. Additionally, studies using MSCs 
derived from adipose [72-74] and synovium [75], or using MSC-seeded tissue constructs 
[76-80] have confirmed the validity of MSCs in disc regeneration therapy.
It should be mentioned, however, that there are still many issues to be addressed before this 
therapeutic strategy can be successfully implemented in clinical settings. For example, 
Vadalà et al. [81] showed that MSCs injected into degenerative rabbit discs leaked and 
migrated out of the NP, forming large anterolateral osteophytes. This indicates the needs to 
develop more precise cell delivery systems or to use annulus-sealing techniques. Another 
important issue to consider in MSC transplantation is availability of nutrients and the 
degenerative state of the IVD microenvironment, which will significantly influence survival 
and activity of transplanted MSCs [82]. Nutrient deprivation is important factor in disc 
degeneration, and as such nutrient supply and demand is tightly regulated in healthy IVD. 
Addition of growth factors to supplement transplanted MSCs can thus further exacerbate 
already low nutrient level in degenerate disc by stimulating cell metabolism [83]. 
Considering this, MSC transplantation may be better suited as an early interventional 
therapy for disc degeneration.
The overall results of the in vitro and in vivo studies from using MSC and progenitor cells in 
disc regeneration are promising. However, it is important to note that most of these studies 
investigating MSC differentiation toward an NP cell have evaluated the state of 
differentiation using markers that are either not NP-specific or using an incomplete list of 
NP markers. For example, expression levels of COL2A1, ACAN, and SOX9 are commonly 
used to determine MSC acquisition of NP phenotypes [42, 43, 45, 46, 51-53]. Despite the 
fact that these genes are known to be expressed by healthy adult human NP cells [84], they 
are also typically expressed by chondrocytes. Minogue et al. [67] reported results of a 
microarray study comparing bovine NP, AF, and articular cartilage (AC) cells. The authors 
identified 34 genes specific to NP and 49 specific to either type of IVD-derived cell. Out of 
those chosen for qRT-PCR validation in human NP cells, 11 genes (SNAP25, K8, K18, 
K19, CDH2, IBSP, VCAN, TNMD, BASP1, FOXF1, and FBLN1) were confirmed. In 
addition, the study identified several putative “negative NP markers” – genes with lower 
expression in NP than the other tissues studied. The same group went on to use microarray-
identified markers to distinguish NP-like differentiation in BM-MSCs and AD-MSCs [85]. 
Here, the authors differentiated both types of MSCs in collagen I gels before measuring 
expression levels of marker genes. They identified and validated five NP marker genes: 
PAX1, FOXF1, HBB, CAXII, and OVOS2 to validate differentiation to an NP-like 
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phenotype. Differentiated MSCs showed significant increase in expression levels of classical 
markers COL2A1 and ACAN as well as PAX1 and FOXF1. In addition, both types of MSCs 
lacked expression of at least one AC marker following differentiation. This study again 
demonstrated the utility of a negative NP marker: IBSP, which was differentially expressed 
in the human samples. Since in this study differentiated BM-MSCs expressed negative NP 
markers FBLN1 and IBSP as opposed to AD-MSCs, the authors suggest that AD-MSCs 
may represent a superior cell type for differentiation to an NP-like phenotype. Some studies 
investigating transplantation of AD-MSCs also suggest their advantage over using BM-
MSCs due to convenience of isolation and ready availability of starting material [72-74].
Establishing a clear and complete definition of NP cell phenotype is therefore required in 
order to utilize the concept of cell “markers” for differentiation.
MARKERS SPECIFIC TO CELL FUNCTION IN THE NP 
MICROENVIRONMENT
Two characteristic features of the nucleus pulposus microenvironment are 1) lack of 
vascularization, which creates a physiologically hypoxic environment, and 2) high content 
of water-binding proteoglycans, which elevates osmotic pressure outside of cells. It is 
therefore critical that cells transplanted into the NP are able to perform under these 
conditions. The ability of resident NP cells to survive, proliferate, and function within either 
unique microenvironment has been largely attributed to expression of two transcription 
factors: HIF-1α and tonicity-responsive enhancer binding protein (TonEBP/NFAT5).
The healthy IVD is physiologically hypoxic [86, 87] and vascular invasion of the disc is, in 
fact, associated with nerve ingrowth and pain [88, 89]. Therefore, cells transplanted into the 
NP must have mechanisms to cope with a low oxygen environment. The HIF family of 
transcription factors are responsible for activating an adaptive cellular response in cells 
exposed to hypoxia [90]. Under normoxic conditions, the HIF-α subunit, necessary for 
transcriptional activity, is targeted for proteasome-mediated degradation by selective 
hydroxylation of conserved proline residues by members of the prolyl hydroxylase family 
(PHDs). In hypoxia, prolyl hydroxylation cannot proceed, leaving the α subunit to dimerize 
with the β subunit and bind DNA in the nucleus [91]. Careful work by Risbud and 
coworkers has shown that NP cells constitutively express HIF-1α and HIF-2α under both 
normoxia and hypoxia [92, 93]. Consistent with this observation, alternative oxygen-
independent means of HIF-α degradation and activity have been shown to impact protein 
levels in NP cells [94-96]. Taken together, unique regulation of HIF protein turnover and 
activity in NP cells suggests its importance in NP physiology. Further evidence for this 
comes from a recent mouse model of selective HIF-1α loss in the NP, demonstrating the 
necessity of this protein for cell survival [56, 97]. In their study, Merceron et al. 
demonstrated that tissue-specific conditional knockout of HIF-1α in notochordal cells 
resulted in morphologic changes of NP cells at E15.5, and complete disappearance by 1-
month of age [56]. This was attributed to necessity of HIF-1 in driving metabolic and 
synthetic activities of NP cells in vivo, as was shown by previous in vitro studies [92, 98]. In 
addition to these pro-glycolysis targets, HIF has been shown to regulate expression of key 
matrix related genes in the NP such as ACAN [98, 99]. β−1,3-glucuronyltransferase 1 
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(GlcAT-I) [100], galectin 3 [101]. CAXII has been proposed as a marker of healthy human 
NP tissue [102]. This is not unexpected, as carbonic anhydrases play an important role in 
controlling pH balance, critical in a hypoxic tissues such as the solid tumors or the NP [103]. 
CAXII is hypoxia inducible in tumor cells, although a HIF-responsive element (HRE) has 
not yet been found [104]. Therefore, it is possible that other members of the CA family can 
serve as functional NP markers. Noteworthy, expression of CAII, CAIII, and CAVI has been 
shown in embryonic mouse notochord and/or NP [105]. In addition, robust expression of 
CAIII transcripts in early notochordal and NP has been shown [106].
In the healthy disc, water content of the NP is approximately 77% [107]. It is this 
hydrostatic pressure, deriving from the high concentration of water-binding aggrecan and 
other proteoglycans, which gives the disc its ability to resist compressive forces. As a result 
of this architecture, normal daily movement causes frequent fluctuations in extracellular 
osmolarity of the disc [108, 109] with values ranging from 430 to 496 mOsm [110, 111]. 
Robust expression of the osmosensitive transcription factor TonEBP allows NP cells to 
sustain normal cellular activities under this daily hypertonic fluctuations [112, 113]. 
Normally, mammalian cells in a hypertonic environment activate membrane electrolyte 
transporters to balance inter- and extracellular solute concentrations. This response increases 
the osmotic pressure inside the cell, which can damage DNA and lead to autophagy, 
senescence or apoptosis if sustained [114]. To relieve intracellular osmotic pressure, 
TonEBP drives expression of several genes essential in the exchange of accumulated 
charged ions for small organic non-ionic osmolytes [115, 116]. Indeed, TonEBP expression 
is required for NP cell survival in hypertonic medium and occurs most likely via 
transcriptional activation of canonical target genes sodium myoinositol transporter (SMIT), 
betaine-γ-amino butyric acid transporter (BGT1), and taurine transporter (TauT) [113]. In 
addition, TonEBP in NP cells drives expression of ACAN [113, 117], GlcAT-I, needed for 
chondroitin sulfate chain synthesis [118], and the water channel protein aquaporin 2 (AQP2) 
[119]. Although not a classic “cell marker,” the robust expression and responsiveness of 
TonEBP in the NP is certainly required for survival under physiological conditions of the 
disc. In addition, TonEBP allows NP cells to uniquely modify their extracellular matrix in 
response to osmotic stimuli [112]. As such, any cell destined for the stressful NP 
microenvironment should exhibit similar expression of these transcription factors and 
activation of their targets.
MARKERS OF EXTRACELLULAR MATRIX CONTENT
As described above, the matrix produced by cells of the NP and resulting hydrostatic 
pressure is of utmost functional importance for the disc. It is therefore prudent to consider 
the major matrix molecules produced by resident cells of the NP. The most abundant 
proteoglycan in the NP is ACAN, with lesser amounts of versican (VCAN), biglycan 
(BGN), decorin (DCN), and fibromodulin (FMOD) present in the tissue [9]. In addition to 
proteoglycans, collagens make up a substantial component of the NP matrix, mainly 
collagen II [10]. It is important to note that, despite expression of ACAN and collagen II in 
both chondrocytes and NP cells, the ratios of these molecules can be used to differentiate 
between matrices produced by the two cell types. This ratio has been measured as the GAG 
to hydroxyproline ratio, which Mwale et al. showed to be about 27:1 in the young adult NP 
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and about 2:1 in hyaline cartilage [120]. Given that the GAG to hydroxyproline ratio 
decreased with increased histological grade of disc degeneration in this study, maintenance 
of a proteoglycan-rich matrix may signify ideal NP cell function. With the importance of 
cell-matrix interaction in mind, Chen et al [121] investigated expression levels of lamin 
chains, integrins, and other matrix binding proteins in NP tissues, finding that compared to 
surrounding AF, NP tissue had elevated expression of laminin α5 chain, integrin subunits 
α3, α6, and β4, CD239, and CD151. In a follow-up study, the same group showed integrins 
α3, α5, and β1 were important for NP attachment to laminin isoforms LM-111 and LM-511 
[122].
CONCLUSIONS
Degeneration of the intervertebral discs is a ubiquitous and chronic condition. While there 
have been strides in the field to better understand cell function and pathophysiology, 
complete recovery of disc function and alleviation of pain still remains a major problem. 
Regenerative therapies, both those that harness the intrinsic capacity of native progenitor 
cells in the NP and those that rely on transplanted cells, may lead the way in disease 
treatment. However, the success of these therapies is dependent upon recapitulation of a 
healthy NP cell and tissue phenotype. From a standpoint of cell introduction to the NP, it is 
crucial that the cells express factors allowing for their survival, such as HIF-1α and 
TonEBP. Therefore, consideration of both functional markers and cell surface markers, such 
as Tie2, GD2, or CD24 and others for cell sorting, will be useful in future investigations on 
cell-based therapy for disc degeneration.
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Figure 1. 
Decrease of Tie2+ NP cells with ageing and degeneration. Human NP cells donated by 
patients were studied together with their clinical profiles. Cells were freshly dispersed and 
only cells detected by flow cytometry within the live and the PI-negative gate were 
analysed. (a) Representative flow cytometry data of Tie2 and GD2 cell positivity in different 
age groups. (b) The frequency of Tie2+ cells (T/sp and TG/dp hNP cells) began to decrease 
before 20 years of age and correlated negatively with age (n=23, R2=0.9224). (c) The 
frequency of hNP-CFU-S generation also decreased with age (n=23, R2=0.8665). (d) The 
frequency of Tie2+ cells (T/sp and TG/dp hNP cells) decreased in relation to the extent of 
disc degeneration graded by morphology and (e) with disc degeneration graded by 
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diagnostic magnetic resonance imaging (n=11). (f) The frequency of hNP-CFU-S generation 
decreased in relation to the extent of disc degeneration graded by morphology (n=23). 
*P<0.05, **P<0.01 (ANOVA with Mann–Whitney U-test). Data are represented as mean
±s.d. Adapted from Ref. 27.
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Figure 2. 
Schematic diagram showing cell based therapy strategy for disc regeneration. Mesenchymal 
stem cells (MSCs) can be derived from either bone marrow (BM-MSCs) or adipose (AD-
MSCs), before undergoing differentiation into NP-like cells through various treatments. 
Alternately, NP progenitor cells may be identified with markers and isolated directly from 
healthy disc tissue. Confirmation of NP cell phenotype as defined by functional, tissue-of-
origin, and other markers unique to NP cells before transplantation is necessary for 
successful disc regeneration.
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